HCPCS Level II code J7314 denotes the intravitreal implant injection of fluocinolone acetonide (Yutiq), 0.01 mg, a sustained-release corticosteroid placed directly into the vitreous cavity for long-term intraocular inflammation control. This code matters nationally because it captures utilization and billing for a specialty ophthalmic drug-procedure combination that has implications for outpatient ophthalmology practice patterns, payer coverage policies, and drug spend for sight-threatening inflammatory eye diseases.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of the implant, typical sites of service where the procedure is performed, and coding specifics tied to billing the intravitreal implant. The publication outlines payer coverage considerations, common billing modifiers, and benchmarking subjects relevant to facilities and clinicians who perform intravitreal drug implantation.

The piece also summarizes typical reimbursement and claim-line considerations, notes on billing workflow for an implanted ophthalmic drug, and areas where policy updates or prior authorization requirements often influence access. Data not available in the input will be identified clearly in relevant sections.